期刊文献+

人凝血因子Ⅶ基因在CHO-K1细胞中的瞬时表达与鉴定

Transient expression and identification of human coagulation factor Ⅶ in CHO-K1 cell
下载PDF
导出
摘要 目的在CHO-K1细胞中瞬时表达所克隆的人凝血因子Ⅶ(FⅦ)的cDNA序列并表达其产物。方法首先从HepG2细胞中克隆人FⅦcDNA序列,将克隆得到的序列连接到pMD18-T载体上经测序验证后,将其与pcDNA3.1载体连接,构建得到重组表达质粒pcDNA3.1-FⅦ。将构建得到的表达质粒瞬时转染CHO-K1细胞,72 h取样,采用ELISA、Western blotting等方法对细胞上清液和细胞裂解物作鉴定。结果克隆得到的序列经NCBI比对后为FⅦ转录突变体Ⅱ基因序列,克隆得到的基因未见氨基酸突变,重组表达质粒pcDNA3.1-FⅦ经PCR、双酶切、测序验证正确。ELISA法未在上清中检测到目的蛋白,而在细胞裂解液中检测到了目的蛋白;Western blotting检测到表达产物有与FⅦ标准品类似的分子量为50 kD左右的特异性条带。结论在转染后的CHO-K1细胞裂解液上清中成功表达了hFⅦ蛋白。 Objective To transient express the human coagulation factor Ⅶ gene in CHO-K1 cell. Methods The hu- man coagulation factor Ⅶ cDNA was amplified from total RNA of HepG2 cell line using RT-PCR. After identified by DNA se- quencing,the correct cDNA was cloned into pcDNA3.1 vector to get expression vector pcDNA3.1-FⅦ which was transfected into CHO-K1 cell. Culture supernatant and cell lysate were collected at 72 h after transfection and detected by Western blot- ting and ELISA. Results Sequence analysis showed that the fragment we obtained was the human coagulation factor Ⅶ tran- script variant Ⅱ gene, and further analysis demonstrated that no amino acid was changed in the sequence. The pcDNA3.1-FⅦ expression vector was constructed correctly by PCR and enzyme cut. ELISA showed that hFⅦ was detected in the cell lysate but not in the culture supernatant, and Western blotting further confirmed that the protein was approximately 50 kD. Conclu- sion Human coagulation factor VII was succefully expressed in CHO-K1 cell lysate.
出处 《中国输血杂志》 CAS CSCD 北大核心 2013年第10期990-993,共4页 Chinese Journal of Blood Transfusion
关键词 人凝血因子VII CHO—K1细胞 克隆 基因表达 human coagulation factor Ⅶ CHO-K1 cell clone gene expression
  • 相关文献

参考文献17

  • 1Davie KW,Fujikawa K,Kurachi K et al The role of serine proteasesin the blood coagulation cascade.Adv Knzymol Relat Areas Mol Hi-ol,1979,48:277-318.
  • 2Frederick SH,Charles I G,Patrick OH,,et al.Characterization of acDNA coding for human factor Ⅶ(blood coagulation / DNA se-quence / vitamin K-dependent proteins).Proc Natl Acatl Sci USA,1986,83(4):2412-2416.
  • 3Discipio RG,Heimotlson MA,Yates SG,et al.A comparison of hu-man prothrombin factor Ⅸ(Chrisnms factor)factor Ⅹ(Stuart fac-tor)ami protein S.Biochemistiy,1977,16(4):698-706.
  • 4Patrick J.O'HARA,Francis J,et al.Nucleotide sequence of the genecoding for human factor Ⅶ,a vitamin K-dependent protein participat-ing in blood coagulation.PNAS,1987,84,pp.(8)5158-5162.
  • 5Kisiel W,Davie EW,Isolation and characterization of bovine factor Ⅶ Biochemistry,1975,14(22):4928-4934.
  • 6Radcliffe R,Nemerson Y.Activation and control of factor Ⅶ by acti-vated factor Ⅹ and thrombin,isolation and characterization of a singlechain form of factor Ⅶ.J Biol Chem,1975,250(2):388-395.
  • 7Miletich JP,Broze GJ,Majerus PW.The synthesis of sulfated dextranbeads for isolation of human plasma coagulation factorsⅡ Ⅸ and Ⅹ.Hu-man factor Ⅶ.Methods and Enzymol,1980,105(2):304-310.
  • 8Radcliffe R,Bagdasarian S,Colman R,et al.Activation of bovine factor Ⅶ by factor Hageman fragments.Blood,1977,50(4):611-617.
  • 9Kisiel W,Fujikawa K,Davie EW.Activation of factor Ⅶ(procon-vertin)by factor Ⅻ a.(activated Hageman factor).Biochemistry,1977,16(19);4189-4194.
  • 10Seligsohn U,Osterud B,Brown SF,et al.Activation of human factorVl in plasma and in purified system:role of activated factor Ⅸ,Kal-likrein,and activated factor Ⅻ.J Chin Invest,1979,64(4):1056-1065.

二级参考文献21

  • 1Martinowitz U, Kenet G, Onaca MD, et al. New treatment of un controlled hemorage in trauma/surgical patients: induction of local hypercoagulation [A]. In: American Association for the Surgery of Trauma 60th Annual Meeting, Session Ⅸ[C]. Texas: San Antoni
  • 2Sabater-Lleal M, Martinez-Marchan E, Martinez-Sanchez E, et al.Complexity of the genetic contribution to factor Ⅶ deficiency in two Spanish families: clinical and biological implications [J].Haematologica, 2003,88(8):906
  • 3Erhardtsen E, Nony P, Dochavanne M, et al. The effect of recom binant factor Ⅶa (NovoSeven) in healthy volunteers receiving a cenocoumarol to an International Normalized Ratio above 2.0 [J].Blood Coagul Fibrinolysis, 1998,9:741
  • 4Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant facotor Ⅶa (NovoSeven) in haemophiliacs with inhibitors[J]. Thromb Haemost, 1998,80:912
  • 5Hedner U, Ljundberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FⅦa in vitro and in a rabbit model[J]. Blood Coagul Fibrinolysis, 1990,1(2):145
  • 6Hagen F, Gray L, O′Hara P, et al. Characterization of a cDNA coding for human factor Ⅶ[J]. Proc Natl Acad Sci USA, 1986,83:2412
  • 7Bladbjerg EM, Gram J, Jespersen J. Plasma concentrations of blood coagulation factor Ⅶ measured by immunochemical and amidolytic methods[J]. Scand J Clin Lab Invest, 2000,60(3):161
  • 8Rivard GE, Kovac Ⅰ, Kunschak M, et al. Clinical study of recovery and half-life of vapor-heated factor Ⅶ concentrate[J]. Transfusion, 1994,34( 11 ):975
  • 9Goudemand J, Caron C, Dreyfus M, et al. Standardization of factor Ⅶ/activated factor Ⅵ measurement in plasma of patients treated with recombinant factor activated Ⅶ[J]. Blood Coagul Fibrinolysis,2003,14(5):505
  • 10Thim L, Bjoern S, Christensen M, et al. Amino acid sequence and posttranslational modifications of human factor Ⅶ a from plasma and transfected baby hamster kidney cells[J]. Biochemistry, 1988,27:7785

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部